1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Pipeline Review, H1 2020, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.
Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 3, 1, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Peptic Ulcers - Overview
- Peptic Ulcers - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Peptic Ulcers - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peptic Ulcers - Companies Involved in Therapeutics Development
- Axsome Therapeutics Inc
- Balto Therapeutics
- CalyGene Biotechnology Inc
- Chong Kun Dang Pharmaceutical Corp
- Daewoong Pharmaceutical Co Ltd
- FortuneRock (China) Ltd
- Hunan Mingrui Pharmaceutical Co Ltd
- Hunan Sailong Pharmaceutical Co Ltd
- Ilyang Pharmaceutical Co Ltd
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- PharmaKing Co Ltd
- RaQualia Pharma Inc
- Sama Pharm Co Ltd
- Wooridul Pharmaceutical Ltd
- XuanZhu Pharma Co Ltd
- Peptic Ulcers - Drug Profiles
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- CG-20043 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dexlansoprazole - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dexlansoprazole - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fexuprazan - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- glycopyrrolate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ilaprazole DR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KBP-3571 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pantoprazole sodium - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PMKS-005 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- rabeprazole sodium - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SA-15001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SFR-9X0123 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tegoprazan - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- WRDN-002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Peptic Ulcers - Dormant Projects
- Peptic Ulcers - Discontinued Products
- Peptic Ulcers - Product Development Milestones
- Featured News & Press Releases
- Feb 13, 2020: Sihuan Pharmaceutical Holdings Group: Commencement of phase III clinical trial in the PRC for self-developed innovative patented drug Anaprazole Sodium
- Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China
- Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
- Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
- Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
- Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
- Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
- Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
- Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
- Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
- Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
- Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
- Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
- Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
- Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Peptic Ulcers, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Peptic Ulcers - Pipeline by Axsome Therapeutics Inc, H1 2020
- Peptic Ulcers - Pipeline by Balto Therapeutics, H1 2020
- Peptic Ulcers - Pipeline by CalyGene Biotechnology Inc, H1 2020
- Peptic Ulcers - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020
- Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by FortuneRock (China) Ltd, H1 2020
- Peptic Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by PharmaKing Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H1 2020
- Peptic Ulcers - Pipeline by Sama Pharm Co Ltd, H1 2020
- Peptic Ulcers - Pipeline by Wooridul Pharmaceutical Ltd, H1 2020
- Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1 2020
- Peptic Ulcers - Dormant Projects, H1 2020
- Peptic Ulcers - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Peptic Ulcers - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Peptic Ulcers, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Axsome Therapeutics Inc
- Balto Therapeutics
- CalyGene Biotechnology Inc
- Chong Kun Dang Pharmaceutical Corp
- Daewoong Pharmaceutical Co Ltd
- FortuneRock (China) Ltd
- Hunan Mingrui Pharmaceutical Co Ltd
- Hunan Sailong Pharmaceutical Co Ltd
- Ilyang Pharmaceutical Co Ltd
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- PharmaKing Co Ltd
- RaQualia Pharma Inc
- Sama Pharm Co Ltd
- Wooridul Pharmaceutical Ltd
- XuanZhu Pharma Co Ltd
